Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Lanreotide kontra placebo före operationen för att förhindra en kirurgisk komplikation som kallas en bukspottkörtelfistel

4 november 2026 uppdaterad av: SWOG Cancer Research Network

En randomiserad fas III blindad studie av lanreotid för att förebygga postoperativ bukspottkörtelfistel

This phase III trial compares the effect of using lanreotide before surgery to surgery alone in preventing pancreatic fistulas in patients with pancreatic cancer or a pancreatic lesion that could become cancerous. Lanreotide, a type of somatostatin analog similar to somatostatin (a hormone made by the body), and is used to treat certain types of gastroenteropancreatic neuroendocrine tumors, and carcinoid syndrome. It may help stop the body from making extra amounts of certain hormones, including growth hormone, insulin, glucagon, and hormones that affect digestion. It may also help keep certain types of tumor cells from growing. Patients with pancreatic cancer or pancreatic lesions may undergo surgery to remove parts of the pancreas, also called a distal pancreatectomy. Patients may experience complications after surgery, including pancreatic fistulas. A pancreatic fistula occurs when there is a small leak from the pancreas, causing fluids to collect. This can often lead to infection and other problems. Giving lanreotide before undergoing distal pancreatectomy may be more effective than surgery alone in preventing the development of a pancreatic fistula in patients with pancreatic cancer or a pancreatic lesion that could become cancerous.

Studieöversikt

Detaljerad beskrivning

PRIMARY OBJECTIVE:

I. To compare the incidence of postoperative pancreatic fistula (POPF) occurring within 60 days after surgery in participants randomized to receive preoperative lanreotide versus placebo prior to undergoing distal pancreatectomy for biopsy-proven or suspected neoplasm.

SECONDARY OBJECTIVES:

I. To compare the incidence of International Study Group of Pancreatic Surgery (ISGPS)-defined biochemical leak occurring within 60 days after surgery in participants randomized to receive preoperative lanreotide versus placebo in the subset of participants with a drain placed.

II. To compare the number of postoperative days in the hospital within 60 days after surgery in participants randomized to receive preoperative lanreotide versus placebo.

III. To compare change from baseline in cancer-specific quality of life at 14 and 60 days after surgery, as measured by the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) Core 30-(C30), in participants randomized to receive preoperative lanreotide versus placebo.

ADDITIONAL OBJECTIVES:

I. To compare change from baseline in pancreatic cancer-specific quality of life and overall health-related quality of life at 14 and 60 days after surgery, as measured by the EORTC QLQ- Pancreatic Cancer 26 (PAN26) and European Quality of Life Five Dimension Five Level (EQ-5D-5L), in participants randomized to receive preoperative lanreotide versus placebo.

II. To compare the proportions of participants with common postoperative sequelae associated with POPF, including ISGPS delayed gastric emptying and ISGPS post pancreatectomy hemorrhage (grades B/C) occurring within 60 days after surgery, in participants randomized to receive preoperative lanreotide versus placebo.

III. To compare time from surgery to initiation of adjuvant chemotherapy among participants with pancreatic ductal adenocarcinoma and planned adjuvant chemotherapy randomized to receive preoperative lanreotide versus placebo.

BANKING OBJECTIVE:

I. To bank blood, pancreas fluid, and tissue specimens for future correlative studies.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Patients receive lanreotide subcutaneously (SC) over 20 seconds and within 36 hours of planned distal pancreatectomy. Patients also undergo blood sample collection immediately prior to surgery and on post-operative days 1 and 3. Additionally, patients may undergo collection of pancreas fluid on post-operative days 1 and 3.

ARM II: Patients receive saline placebo SC over 20 seconds and within 36 hours of planned distal pancreatectomy. Patients also undergo blood sample collection immediately prior to surgery and post-operatively on days 1 and 3. Additionally, patients may undergo collection of pancreas fluid on post-operative days 1 and 3.

After completion of study treatment, patients are followed up at 4, 8 and 12 months after surgery.

Studietyp

Interventionell

Inskrivning (Beräknad)

274

Fas

  • Fas 3

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studera Kontakt Backup

Studieorter

    • Alabama
      • Birmingham, Alabama, Förenta staterna, 35233
        • Upphängd
        • University of Alabama at Birmingham Cancer Center
      • Daphne, Alabama, Förenta staterna, 36526
        • Upphängd
        • Gulf Health Hospitals Inc/Infirmary Cancer Care - Malbis
      • Fairhope, Alabama, Förenta staterna, 36532
        • Upphängd
        • Thomas Hospital
      • Mobile, Alabama, Förenta staterna, 36607
        • Upphängd
        • Mobile Infirmary Medical Center
      • Saraland, Alabama, Förenta staterna, 36571
        • Upphängd
        • Gulf Health Hospitals Inc/Infirmary Cancer Care - Saraland
    • Arizona
      • Gilbert, Arizona, Förenta staterna, 85234
        • Upphängd
        • Banner MD Anderson Cancer Center
    • California
      • Duarte, California, Förenta staterna, 91010
        • Upphängd
        • City of Hope Comprehensive Cancer Center
      • La Jolla, California, Förenta staterna, 92093
        • Rekrytering
        • UC San Diego Moores Cancer Center
        • Kontakt:
        • Huvudutredare:
          • Andrew M. Lowy
      • Loma Linda, California, Förenta staterna, 92357
        • Upphängd
        • Veterans Affairs Loma Linda Healthcare System
      • Los Angeles, California, Förenta staterna, 90033
        • Upphängd
        • USC / Norris Comprehensive Cancer Center
      • San Diego, California, Förenta staterna, 92103
        • Upphängd
        • UC San Diego Medical Center - Hillcrest
    • Delaware
      • Newark, Delaware, Förenta staterna, 19718
        • Upphängd
        • Christiana Care Health System-Christiana Hospital
      • Newark, Delaware, Förenta staterna, 19713
        • Upphängd
        • Helen F Graham Cancer Center
      • Newark, Delaware, Förenta staterna, 19713
        • Upphängd
        • Medical Oncology Hematology Consultants PA
      • Wilmington, Delaware, Förenta staterna, 19801
        • Upphängd
        • Christiana Care Health System-Wilmington Hospital
    • Florida
      • Ruskin, Florida, Förenta staterna, 33570
        • Upphängd
        • Moffitt Cancer Center at SouthShore
      • Tampa, Florida, Förenta staterna, 33612
        • Rekrytering
        • Moffitt Cancer Center - McKinley Campus
        • Kontakt:
        • Huvudutredare:
          • Andrew J. Sinnamon
      • Tampa, Florida, Förenta staterna, 33607
        • Upphängd
        • Moffitt Cancer Center-International Plaza
      • Tampa, Florida, Förenta staterna, 33612
        • Upphängd
        • Moffitt Cancer Center
      • Wesley Chapel, Florida, Förenta staterna, 33544
        • Upphängd
        • Moffitt Cancer Center at Wesley Chapel
    • Georgia
      • Atlanta, Georgia, Förenta staterna, 30342
        • Upphängd
        • Emory Saint Joseph's Hospital
      • Atlanta, Georgia, Förenta staterna, 30308
        • Upphängd
        • Emory University Hospital Midtown
      • Atlanta, Georgia, Förenta staterna, 30322
        • Upphängd
        • Emory University Hospital/Winship Cancer Institute
      • Atlanta, Georgia, Förenta staterna, 30303
        • Upphängd
        • Grady Health System
      • Johns Creek, Georgia, Förenta staterna, 30097
        • Upphängd
        • Emory Johns Creek Hospital
    • Illinois
      • Chicago, Illinois, Förenta staterna, 60611
        • Rekrytering
        • Northwestern University
        • Kontakt:
        • Huvudutredare:
          • Akhil Chawla
      • Chicago, Illinois, Förenta staterna, 60612
        • Rekrytering
        • University of Illinois
        • Huvudutredare:
          • Aslam Ejaz
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 312-355-3046
      • Geneva, Illinois, Förenta staterna, 60134
        • Upphängd
        • Northwestern Medicine Cancer Center Delnor
      • Oak Brook, Illinois, Förenta staterna, 60523
        • Upphängd
        • Northwestern Medicine Oak Brook
      • Orland Park, Illinois, Förenta staterna, 60462
        • Upphängd
        • Northwestern Medicine Orland Park
      • Warrenville, Illinois, Förenta staterna, 60555
        • Upphängd
        • Northwestern Medicine Cancer Center Warrenville
    • Indiana
      • Indianapolis, Indiana, Förenta staterna, 46202
        • Upphängd
        • Indiana University/Melvin and Bren Simon Cancer Center
    • Kentucky
      • Lexington, Kentucky, Förenta staterna, 40536
        • Rekrytering
        • University of Kentucky/Markey Cancer Center
        • Huvudutredare:
          • Michael J. Cavnar
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 859-257-3379
    • Louisiana
      • New Orleans, Louisiana, Förenta staterna, 70112
        • Upphängd
        • University Medical Center New Orleans
    • Maryland
      • Elkton, Maryland, Förenta staterna, 21921
        • Upphängd
        • Christiana Care - Union Hospital
    • Michigan
      • Ann Arbor, Michigan, Förenta staterna, 48109
        • Upphängd
        • University of Michigan Rogel Cancer Center
      • Battle Creek, Michigan, Förenta staterna, 49017
        • Upphängd
        • Bronson Battle Creek
      • Grand Rapids, Michigan, Förenta staterna, 49503
        • Upphängd
        • Trinity Health Grand Rapids Hospital
      • Grand Rapids, Michigan, Förenta staterna, 49503
        • Upphängd
        • Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
      • Grand Rapids, Michigan, Förenta staterna, 49503
        • Upphängd
        • Corewell Health Grand Rapids Hospitals - Butterworth Hospital
      • Muskegon, Michigan, Förenta staterna, 49444
        • Upphängd
        • Trinity Health Muskegon Hospital
      • Niles, Michigan, Förenta staterna, 49120
        • Upphängd
        • Corewell Health Lakeland Hospitals - Niles Hospital
      • Norton Shores, Michigan, Förenta staterna, 49444
        • Upphängd
        • Cancer and Hematology Centers of Western Michigan - Norton Shores
      • Reed City, Michigan, Förenta staterna, 49677
        • Upphängd
        • Corewell Health Reed City Hospital
      • Saint Joseph, Michigan, Förenta staterna, 49085
        • Upphängd
        • Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center
      • Saint Joseph, Michigan, Förenta staterna, 49085
        • Upphängd
        • Corewell Health Lakeland Hospitals - Saint Joseph Hospital
      • Wyoming, Michigan, Förenta staterna, 49519
        • Upphängd
        • University of Michigan Health - West
    • Minnesota
      • Aitkin, Minnesota, Förenta staterna, 56431
        • Upphängd
        • Riverwood Healthcare Center
      • Baxter, Minnesota, Förenta staterna, 56425
        • Upphängd
        • Essentia Health - Baxter Clinic
      • Brainerd, Minnesota, Förenta staterna, 56401
        • Upphängd
        • Essentia Health Saint Joseph's Medical Center
      • Crosslake, Minnesota, Förenta staterna, 56442
        • Upphängd
        • Essentia Health - Saint Joseph's Crosslake Clinic
      • Deer River, Minnesota, Förenta staterna, 56636
        • Upphängd
        • Essentia Health - Deer River Clinic
      • Detroit Lakes, Minnesota, Förenta staterna, 56501
        • Upphängd
        • Essentia Health Saint Mary's - Detroit Lakes Clinic
      • Duluth, Minnesota, Förenta staterna, 55805
        • Upphängd
        • Essentia Health Saint Mary's Medical Center
      • Duluth, Minnesota, Förenta staterna, 55805
        • Upphängd
        • Miller-Dwan Hospital
      • Duluth, Minnesota, Förenta staterna, 55805
        • Upphängd
        • Essentia Health Cancer Center
      • Ely, Minnesota, Förenta staterna, 55731
        • Upphängd
        • Essentia Health - Ely Clinic
      • Fosston, Minnesota, Förenta staterna, 56542
        • Upphängd
        • Essentia Health - Fosston
      • Hibbing, Minnesota, Förenta staterna, 55746
        • Upphängd
        • Essentia Health Hibbing Clinic
      • International Falls, Minnesota, Förenta staterna, 56649
        • Upphängd
        • Essentia Health - International Falls Clinic
      • Moose Lake, Minnesota, Förenta staterna, 55767
        • Upphängd
        • Essentia Health - Moose Lake Clinic
      • Park Rapids, Minnesota, Förenta staterna, 56470
        • Upphängd
        • Essentia Health - Park Rapids
      • Pequot Lakes, Minnesota, Förenta staterna, 56472
        • Upphängd
        • Essentia Health - Saint Joseph's Pequot Lakes Clinic
      • Pine River, Minnesota, Förenta staterna, 56474
        • Upphängd
        • Essentia Health - Saint Joseph's Pine River Clinic
      • Sandstone, Minnesota, Förenta staterna, 55072
        • Upphängd
        • Essentia Health Sandstone
      • Staples, Minnesota, Förenta staterna, 56479
        • Upphängd
        • Essentia Health - Saint Joseph's Staples Clinic
      • Virginia, Minnesota, Förenta staterna, 55792
        • Upphängd
        • Essentia Health Virginia Clinic
    • Missouri
      • Farmington, Missouri, Förenta staterna, 63640
        • Rekrytering
        • Parkland Health Center - Farmington
        • Huvudutredare:
          • Bryan A. Faller
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 314-996-5569
      • Sainte Genevieve, Missouri, Förenta staterna, 63670
        • Rekrytering
        • Sainte Genevieve County Memorial Hospital
        • Huvudutredare:
          • Bryan A. Faller
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 314-996-5569
      • St Louis, Missouri, Förenta staterna, 63131
        • Rekrytering
        • Missouri Baptist Medical Center
        • Huvudutredare:
          • Bryan A. Faller
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 314-996-5569
      • Sullivan, Missouri, Förenta staterna, 63080
        • Rekrytering
        • Missouri Baptist Sullivan Hospital
        • Huvudutredare:
          • Bryan A. Faller
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 314-996-5569
      • Sunset Hills, Missouri, Förenta staterna, 63127
        • Rekrytering
        • BJC Outpatient Center at Sunset Hills
        • Huvudutredare:
          • Bryan A. Faller
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 314-996-5569
    • Nebraska
      • Omaha, Nebraska, Förenta staterna, 68198
        • Upphängd
        • University of Nebraska Medical Center
    • Nevada
      • Reno, Nevada, Förenta staterna, 89502
        • Upphängd
        • Renown Regional Medical Center
    • New Jersey
      • Livingston, New Jersey, Förenta staterna, 07039
        • Upphängd
        • Saint Barnabas Medical Center
      • New Brunswick, New Jersey, Förenta staterna, 08903
        • Upphängd
        • Rutgers Cancer Institute of New Jersey
    • New Mexico
      • Albuquerque, New Mexico, Förenta staterna, 87106
        • Upphängd
        • University of New Mexico Cancer Center
    • New York
      • Rochester, New York, Förenta staterna, 14642
        • Upphängd
        • University of Rochester
      • Syracuse, New York, Förenta staterna, 13210
        • Upphängd
        • State University of New York Upstate Medical University
    • North Carolina
      • Charlotte, North Carolina, Förenta staterna, 28203
        • Upphängd
        • Carolinas Medical Center/Levine Cancer Institute
      • Concord, North Carolina, Förenta staterna, 28025
        • Upphängd
        • Atrium Health Cabarrus/LCI-Concord
    • North Dakota
      • Fargo, North Dakota, Förenta staterna, 58103
        • Upphängd
        • Essentia Health Cancer Center-South University Clinic
      • Fargo, North Dakota, Förenta staterna, 58122
        • Upphängd
        • Sanford Roger Maris Cancer Center
      • Fargo, North Dakota, Förenta staterna, 58122
        • Upphängd
        • Sanford Broadway Medical Center
      • Jamestown, North Dakota, Förenta staterna, 58401
        • Upphängd
        • Essentia Health - Jamestown Clinic
    • Ohio
      • Cincinnati, Ohio, Förenta staterna, 45219
        • Upphängd
        • University of Cincinnati Cancer Center-UC Medical Center
      • Columbus, Ohio, Förenta staterna, 43210
        • Upphängd
        • Ohio State University Comprehensive Cancer Center
      • West Chester, Ohio, Förenta staterna, 45069
        • Upphängd
        • University of Cincinnati Cancer Center-West Chester
    • Pennsylvania
      • Allentown, Pennsylvania, Förenta staterna, 18104
        • Rekrytering
        • Saint Luke's Cancer Center - Allentown
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 610-776-4714
        • Huvudutredare:
          • Darius C. Desai
      • Bethlehem, Pennsylvania, Förenta staterna, 18015
        • Rekrytering
        • Saint Luke's University Hospital-Bethlehem Campus
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 484-503-4151
        • Huvudutredare:
          • Darius C. Desai
      • Chadds Ford, Pennsylvania, Förenta staterna, 19317
        • Upphängd
        • Christiana Care Health System-Concord Health Center
      • Easton, Pennsylvania, Förenta staterna, 18045
        • Rekrytering
        • Saint Luke's Hospital-Anderson Campus
        • Kontakt:
        • Huvudutredare:
          • Darius C. Desai
      • Quakertown, Pennsylvania, Förenta staterna, 18951
        • Rekrytering
        • Saint Luke's Hospital - Upper Bucks Campus
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 610-776-4714
        • Huvudutredare:
          • Darius C. Desai
      • Stroudsburg, Pennsylvania, Förenta staterna, 18360
        • Rekrytering
        • Saint Luke's Hospital - Monroe Campus
        • Kontakt:
        • Huvudutredare:
          • Darius C. Desai
      • Wilkes-Barre, Pennsylvania, Förenta staterna, 18711
        • Upphängd
        • Geisinger Wyoming Valley/Henry Cancer Center
    • South Dakota
      • Sioux Falls, South Dakota, Förenta staterna, 57104
        • Upphängd
        • Sanford Cancer Center Oncology Clinic
      • Sioux Falls, South Dakota, Förenta staterna, 57117-5134
        • Upphängd
        • Sanford USD Medical Center - Sioux Falls
    • Tennessee
      • Knoxville, Tennessee, Förenta staterna, 37920
        • Upphängd
        • University of Tennessee - Knoxville
      • Memphis, Tennessee, Förenta staterna, 38120
        • Upphängd
        • Baptist Memorial Hospital and Cancer Center-Memphis
    • Vermont
      • Burlington, Vermont, Förenta staterna, 05405
        • Upphängd
        • University of Vermont and State Agricultural College
      • Burlington, Vermont, Förenta staterna, 05401
        • Upphängd
        • University of Vermont Medical Center
    • Virginia
      • Richmond, Virginia, Förenta staterna, 23235
        • Rekrytering
        • VCU Massey Cancer Center at Stony Point
        • Kontakt:
        • Huvudutredare:
          • Leopoldo J. Fernandez
      • Richmond, Virginia, Förenta staterna, 23298
        • Rekrytering
        • VCU Massey Comprehensive Cancer Center
        • Huvudutredare:
          • Leopoldo J. Fernandez
        • Kontakt:
      • Roanoke, Virginia, Förenta staterna, 24033
        • Upphängd
        • Carilion Roanoke Memorial Hospital
      • Winchester, Virginia, Förenta staterna, 22601
        • Upphängd
        • Valley Health / Winchester Medical Center
    • Washington
      • Seattle, Washington, Förenta staterna, 98195
        • Upphängd
        • University of Washington Medical Center - Montlake
      • Seattle, Washington, Förenta staterna, 98109
        • Upphängd
        • Fred Hutchinson Cancer Center
    • Wisconsin
      • Ashland, Wisconsin, Förenta staterna, 54806
        • Upphängd
        • Northwest Wisconsin Cancer Center
      • Ashland, Wisconsin, Förenta staterna, 54806
        • Upphängd
        • Duluth Clinic Ashland
      • Hayward, Wisconsin, Förenta staterna, 54843
        • Upphängd
        • Essentia Health-Hayward Clinic
      • Hayward, Wisconsin, Förenta staterna, 54843
        • Upphängd
        • Tamarack Health Hayward Medical Center
      • Marshfield, Wisconsin, Förenta staterna, 54449
      • Mukwonago, Wisconsin, Förenta staterna, 53149
        • Upphängd
        • ProHealth D N Greenwald Center
      • Oconomowoc, Wisconsin, Förenta staterna, 53066
        • Upphängd
        • ProHealth Oconomowoc Memorial Hospital
      • Spooner, Wisconsin, Förenta staterna, 54801
        • Upphängd
        • Essentia Health-Spooner Clinic
      • Superior, Wisconsin, Förenta staterna, 54880
        • Upphängd
        • Essentia Health Saint Mary's Hospital - Superior
      • Waukesha, Wisconsin, Förenta staterna, 53188
        • Upphängd
        • ProHealth Waukesha Memorial Hospital
      • Waukesha, Wisconsin, Förenta staterna, 53188
        • Upphängd
        • UW Cancer Center at ProHealth Care

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Participants must have histologically or radiographically confirmed diagnosis of pancreatic cancer or a pancreatic lesion with malignant potential

  • Participants must have an elective distal pancreatectomy planned to occur within 60 days after registration/randomization date

  • Participants must not have a known history of a prior diagnosis of malabsorption syndrome

  • Participants must not have been treated with any somatostatin analogue within 180 days prior to registration/randomization

  • Participants must not have been treated with radiation therapy for their pancreas malignancy at any time prior to registration/randomization

  • Participants must not have been treated with peptide receptor radionuclide therapy (PRRT) at any time prior to registration/randomization

  • Participants must be ≥ 18 years old

  • Participants must have a complete documented medical history and physical exam within 28 days prior to registration/randomization

  • Participants must have a creatinine ≤ the institutional upper limit of normal (IULN) OR a measured OR calculated creatinine clearance ≥ 50 mL/min using the following Cockcroft -Gault formula within 60 days prior to registration/randomization

  • Participants must complete a pre-registration screening to identify any of the medications below, allowing the study team and treating physician to develop a monitoring plan as needed. Participants taking medications with known interactions with lanreotide may remain eligible if appropriate monitoring and management are in place. These medications include:

    • Diabetes medications (insulin or oral hypoglycemics): Blood sugar will be monitored, and medication dose adjustments made as needed
    • Cyclosporine: Dosage adjustments may be required to maintain therapeutic levels
    • Bromocriptine: Dose adjustments may be considered to account for absorption changes
    • Heart medications (e.g., beta blockers): Heart rate will be monitored, and medication doses adjusted if necessary
    • CYP3A4-metabolized medications: Dose adjustments may be considered to avoid increased exposure
  • In the opinion of the treating surgeon, based on preoperative data, the participant must not require a modified Appleby-type procedure (distal pancreatectomy with celiac axis resection) or multivisceral resection (e.g., stomach, colon, etc.) at the time of distal pancreatectomy

    • NOTE: planned removal of the gallbladder or spleen at the time of distal pancreatectomy is not considered multivisceral resection and is permissible
  • In the opinion of the treating surgeon, based on preoperative data, the participant must not require a tumor enucleation

  • Participants must not have moderate to severe hepatic impairment as defined by liver enzyme elevation more than 5 times the institutional upper limit of normal (either aspartate aminotransferase [AST] > 190 U/L or alanine aminotransferase [ALT] > 320 U/L) within 60 days prior to registration/randomization. Transient elevation at the time of screening that resolves prior to study enrollment is acceptable

  • Participants must not be pregnant or nursing (nursing includes breast milk fed to an infant by any means, including from the breast, milk expressed by hand, or pumped)

  • Individuals who are of reproductive potential must have agreed to use an effective contraceptive method during the whole period of the study and for three months after the study drug administration, with details provided as a part of the consent process. A person who has had menses at any time in the preceding 12 consecutive months or who has semen likely to contain sperm is considered to be of "reproductive potential." In addition to routine contraceptive methods, "effective contraception" also includes refraining from sexual activity that might result in pregnancy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) including hysterectomy, bilateral oophorectomy, bilateral tubal ligation/occlusion, and vasectomy with testing showing no sperm in the semen

  • Participants must be offered the opportunity to participate in specimen banking

  • Participants who can complete EORTC QLQ-C30, EORTC QLQ-PAN26, and EQ-5D-5L forms in English or Spanish, must be offered the opportunity to participate in the quality-of-life study

  • NOTE: As a part of the OPEN registration process, the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system.

  • Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines

  • For participants with impaired decision-making capabilities, legally authorized representatives may sign and give informed consent on behalf of study participants in accordance with applicable federal, local, and Central Institutional Review Board (CIRB) regulations

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Förebyggande
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Dubbel

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Arm I (lanreotide, distal pancreatectomy)

Patients receive lanreotide SC over 20 seconds and within 36 hours of planned distal pancreatectomy. Patients also undergo blood sample collection immediately prior to surgery and on post-operative days 1 and 3. Additionally, patients may undergo collection of pancreas fluid on post-operative days 1 and 3.

Ancillary studies

Undergo blood sample and pancreas fluid collection

Andra namn:
  • Biologisk provsamling
  • Bioprov insamlat
  • Provsamling

Undergo distal pancreatectomy

Given SC

Andra namn:
  • Ipstyl
  • Somatulin
  • Angiopeptin
  • BIM-23014
  • DC 13116
  • Dermopeptin
  • Somatulina
Placebo-jämförare: Arm II (saline placebo, distal pancreatectomy)

Patients receive saline placebo SC over 20 seconds and within 36 hours of planned distal pancreatectomy. Patients also undergo blood sample collection immediately prior to surgery and post-operatively on days 1 and 3. Additionally, patients may undergo collection of pancreas fluid on post-operative days 1 and 3.

Ancillary studies

Undergo blood sample and pancreas fluid collection

Andra namn:
  • Biologisk provsamling
  • Bioprov insamlat
  • Provsamling

Undergo distal pancreatectomy

Given SC

Andra namn:
  • Natriumklorid 0,9 %
  • Normal saltlösning
  • ISOTONISK NATRIUMKLORIDLÖSNING

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Incidence of postoperative pancreatic fistula (POPF)
Tidsram: Up to 60 days after distal pancreatectomy

POPF will be assessed using the 2016 International Study Group for Pancreas Surgery (ISGPS). Incidence rates of POPF in each treatment arm will be described, and treatment arm differences assessed via logistic regression model with adjustment for stratification factor.

Up to 60 days after distal pancreatectomy

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Incidence of biochemical leak (BL)
Tidsram: Up to 60 days after distal pancreatectomy

BL will be defined by the ISGPS as a peritoneal drain amylase greater than three times the upper limit of the institutional normal serum amylase without an effect on clinical management or duration of hospital stay. BL will only be measured in those who had a peritoneal drain placed. Treatment arm differences will be assessed via logistic regression model with adjustment for stratification factor.

Up to 60 days after distal pancreatectomy
Number of post-operation hospital days
Tidsram: From the time of surgery up to 60 days after distal pancreatectomy

Mean hospital length of stay will be compared according to treatment arm via linear regression model with adjustment for stratification factor.

From the time of surgery up to 60 days after distal pancreatectomy
Change in overall quality of life (QOL)
Tidsram: At baseline and at 14 and 60 days after surgery

Assessed using the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life (QLQ) Core 30 (C30). Treatment arm differences in EORTC QLQ-C30 changes will be assessed by repeated measures linear regression model as a function of randomization assignment, baseline score, stratification factor, and visit. Robust standard errors will be estimated via generalized estimating equations to adjust for correlation between repeated outcome measures.

At baseline and at 14 and 60 days after surgery

Andra resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Changes in pancreatic specific QOL
Tidsram: At baseline and up to 60 days after distal pancreatectomy

Will be assessed using EORTC QLQ- Pancreatic Cancer 26. Treatment arm differences in changes from baseline will be assessed by repeated measures linear regression model as a function of randomization assignment, baseline score, stratification factor, and visit. Robust standard errors will be estimated via generalized estimating equations to adjust for correlation between repeated outcome measures.

At baseline and up to 60 days after distal pancreatectomy
Change in health-related QOL
Tidsram: At baseline and up to 60 days after distal pancreatectomy

Will be assessed using the European Quality of Life Five Dimension Five Level scale. Treatment arm differences in changes from baseline will be assessed by repeated measures linear regression model as a function of randomization assignment, baseline score, stratification factor, and visit. Robust standard errors will be estimated via generalized estimating equations to adjust for correlation between repeated outcome measures.

At baseline and up to 60 days after distal pancreatectomy
Delayed gastric emptying (DGE)
Tidsram: Up to 60 days after distal pancreatectomy

DGE will be defined by the ISGPS as reinsertion or persistence of a nasogastric tube after postoperative day (POD) 3 or inability to tolerate solid oral intake by POD 7. Treatment arm differences in the proportion of participants with DGE will be assessed via logistic regression model with adjustment for stratification factor.

Up to 60 days after distal pancreatectomy
Incidence of grades B/C post-pancreatectomy hemorrhage (PPH)
Tidsram: Up to 60 days after distal pancreatectomy

PPH will be defined by the ISGPS as postoperative intra- or extra-luminal hemorrhage requiring transfusion of fluid or blood, intensive care unit transfer, therapeutic endoscopy, endovascular embolization, or reoperation. Treatment arm differences in the proportion of participants with PPH will be assessed via logistic regression model with adjustment for stratification factor.

Up to 60 days after distal pancreatectomy
Time to initiation of adjuvant chemotherapy
Tidsram: From date of surgery to date of first dose of adjuvant chemotherapy up to 60 days after distal pancreatectomy

Distributions of time from surgery to initiation of adjuvant chemotherapy, among participants with planned adjuvant chemotherapy, in each arm will be estimated via cumulative incidence and compared using the stratified log-rank test.

From date of surgery to date of first dose of adjuvant chemotherapy up to 60 days after distal pancreatectomy
Incidence of nausea and vomiting
Tidsram: Up to 60 days after distal pancreatectomy

Proportions of participants with any nausea/vomiting will be compared between treatment arms via Fisher's exact test.

Up to 60 days after distal pancreatectomy

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Jonathan G Sham, SWOG Cancer Research Network

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

9 maj 2025

Primärt slutförande (Beräknad)

1 april 2029

Avslutad studie (Beräknad)

1 april 2029

Studieregistreringsdatum

Först inskickad

29 januari 2025

Först inskickad som uppfyllde QC-kriterierna

29 januari 2025

Första postat (Faktisk)

4 februari 2025

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

6 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

4 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

produkt tillverkad i och exporterad från U.S.A.

Ja

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera